Navigation Links
Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call

ROCKVILLE, Md., May 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 first quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, May 8, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on Friday, May 8, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 225 4091 (International: 1 (703) 639 1128.)

A live audio webcast of the conference call will be available at under Investors/Events. Please connect to this website at east 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning May 8, 2009 at 1:00 p.m. through May 13, 2009 at 11:59 p.m. To access the replay, dial 1 (888) 266 2081 and enter pass code 1357908.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at and in the Company's various filings with the Securities and Exchange Commission.

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Early Retirement of $17 Million of Convertible Debt
2. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
3. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
4. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
6. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
7. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
10. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
11. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):